Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ACIERT
- Development stage
- Phase 1
- Lead developer
- Jilin Tianheng Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ACIERT is an extended-release formulation of acipimox, a nicotinic acid derivative developed by Jilin Tianheng Pharmaceutical. It is indicated for the treatment of lipid disorders, including hypercholesterolemia, hypertriglyceridemia, and type IIb hyperlipoproteinemia. Acipimox acts as an antilipolytic agent by serving as an agonist for the hydroxycarboxylic acid receptor 2 (HCAR2, also known as GPR109A) in adipose tissue. This activation inhibits the release of free fatty acids, thereby reducing the hepatic synthesis of triglycerides and very-low-density lipoproteins (VLDL), which subsequently leads to a reduction in low-density lipoprotein (LDL) cholesterol and an increase in high-density lipoprotein (HDL) cholesterol levels. The extended-release formulation is designed to provide sustained therapeutic levels and potentially mitigate side effects such as cutaneous flushing commonly associated with immediate-release nicotinic acid analogs.
- Brand names
- ACIERT
- Other names
- ACIERT extended-release tabletacipimox extended-release tablet
02
Targets
HCAR2 (Hydroxycarboxylic acid receptor 2)
Beyond the preview
Go deeper on ACIERT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ACIERT.